123 related articles for article (PubMed ID: 36775516)
1. A preliminary descriptive report of the longevity of the effects of Swedish Massage therapy for subjects with Generalized Anxiety Disorder.
Rapaport MH; Schettler PJ; Larson ER; Edwards SA; Dunlop BW; Rakofsky JJ; Kinkead B
J Bodyw Mov Ther; 2023 Jan; 33():176-181. PubMed ID: 36775516
[TBL] [Abstract][Full Text] [Related]
2. Acute Swedish Massage Monotherapy Successfully Remediates Symptoms of Generalized Anxiety Disorder: A Proof-of-Concept, Randomized Controlled Study.
Rapaport MH; Schettler P; Larson ER; Edwards SA; Dunlop BW; Rakofsky JJ; Kinkead B
J Clin Psychiatry; 2016 Jul; 77(7):e883-91. PubMed ID: 27464321
[TBL] [Abstract][Full Text] [Related]
3. Six versus twelve weeks of Swedish massage therapy for generalized anxiety disorder: Preliminary findings.
Rapaport MH; Schettler PJ; Larson ER; Dunlop BW; Rakofsky JJ; Kinkead B
Complement Ther Med; 2021 Jan; 56():102593. PubMed ID: 33197668
[TBL] [Abstract][Full Text] [Related]
4. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial.
Kinkead B; Schettler PJ; Larson ER; Carroll D; Sharenko M; Nettles J; Edwards SA; Miller AH; Torres MA; Dunlop BW; Rakofsky JJ; Rapaport MH
Cancer; 2018 Feb; 124(3):546-554. PubMed ID: 29044466
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of therapeutic massage for generalized anxiety disorder: a randomized controlled trial.
Sherman KJ; Ludman EJ; Cook AJ; Hawkes RJ; Roy-Byrne PP; Bentley S; Brooks MZ; Cherkin DC
Depress Anxiety; 2010 May; 27(5):441-50. PubMed ID: 20186971
[TBL] [Abstract][Full Text] [Related]
6. Dose-response and efficacy of spinal manipulation for care of cervicogenic headache: a dual-center randomized controlled trial.
Haas M; Bronfort G; Evans R; Schulz C; Vavrek D; Takaki L; Hanson L; Leininger B; Neradilek MB
Spine J; 2018 Oct; 18(10):1741-1754. PubMed ID: 29481979
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
[TBL] [Abstract][Full Text] [Related]
8. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial.
Pollack MH; Zaninelli R; Goddard A; McCafferty JP; Bellew KM; Burnham DB; Iyengar MK
J Clin Psychiatry; 2001 May; 62(5):350-7. PubMed ID: 11411817
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of vortioxetine in working patients with generalized anxiety disorder.
Christensen MC; Loft H; Florea I; McIntyre RS
CNS Spectr; 2019 Apr; 24(2):249-257. PubMed ID: 29081307
[TBL] [Abstract][Full Text] [Related]
10. Putative Antidepressant Effect of Chamomile (
Amsterdam JD; Li QS; Xie SX; Mao JJ
J Altern Complement Med; 2020 Sep; 26(9):813-819. PubMed ID: 31808709
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of Shu-gan-qing-re formula for generalized anxiety disorder: study protocol for a multi-center, prospective, double-blind, double-dummy, randomized controlled trial.
Chen P; Zhu H; Ning Y; Yin D; Jia H
Trials; 2020 Mar; 21(1):266. PubMed ID: 32171323
[TBL] [Abstract][Full Text] [Related]
12. Short-term open-label chamomile (Matricaria chamomilla L.) therapy of moderate to severe generalized anxiety disorder.
Keefe JR; Mao JJ; Soeller I; Li QS; Amsterdam JD
Phytomedicine; 2016 Dec; 23(14):1699-1705. PubMed ID: 27912871
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
14. A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder.
Bystritsky A; Kaplan JT; Feusner JD; Kerwin LE; Wadekar M; Burock M; Wu AD; Iacoboni M
J Clin Psychiatry; 2008 Jul; 69(7):1092-8. PubMed ID: 18572984
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.
Davidson JR; DuPont RL; Hedges D; Haskins JT
J Clin Psychiatry; 1999 Aug; 60(8):528-35. PubMed ID: 10485635
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study.
Brawman-Mintzer O; Knapp RG; Nietert PJ
J Clin Psychiatry; 2005 Oct; 66(10):1321-5. PubMed ID: 16259547
[TBL] [Abstract][Full Text] [Related]
17. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
Feusner JD; Kerwin L; Saxena S; Bystritsky A
Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
[TBL] [Abstract][Full Text] [Related]
18. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
Mathew SJ; Garakani A; Reinhard JF; Oshana S; Donahue S
Clin Ther; 2008 Sep; 30(9):1658-66. PubMed ID: 18840371
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD).
Cutler NR; Sramek JJ; Macpherson AE; Doss MG; Benes CO; Howard SF
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):685-94. PubMed ID: 7938559
[TBL] [Abstract][Full Text] [Related]
20. The generalized anxiety spectrum: prevalence, onset, course and outcome.
Angst J; Gamma A; Baldwin DS; Ajdacic-Gross V; Rössler W
Eur Arch Psychiatry Clin Neurosci; 2009 Feb; 259(1):37-45. PubMed ID: 18575915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
